Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Vicore Pharma to Present at Upcoming Investor Conferences

Vicore Pharma Holding

Stockholm, February 26, 2026 – Vicore Pharma Holding AB (Nasdaq Stockholm: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following investor conferences:

  • TD Cowen 46th Annual Health Care Conference
    Location: Boston, USA
    Format: Presentation and 1×1 meetings
    Presentation Date and Time: Wednesday, March 4 at 1:50 PM EST
    Webcast: Link
    Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR and Comms
  • Leerink Partners Global Healthcare Conference 2026
    Location: Miami, USA
    Format: Presentation and 1×1 meetings
    Presentation Date and Time: Monday, March 9 at 11:20 AM EST
    Webcast: Link
    Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR and Comms
  • 2026 Jefferies Biotech on the Beach Summit
    Location: Miami, USA
    Format: 1×1 meetings
    Date: Tuesday, March 10
    Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR and Comms
  • Sweden Life Science Day 2026
    Location: Gothenburg, Sweden
    Format: Presentation
    Presentation Date and Time: Wednesday, March 4 at 9:15 AM CET
    Participant: Hans Jeppsson, CFO

For more information, please contact:
Megan Richards, VP of IR and Comms, +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma 
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
 
Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. www.vicorepharma.com

Attachments
Vicore Pharma to Present at Upcoming Investor Conferences

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.